People with ME have key genetic differences to other people, study finds
Scientists said the findings offer the first robust evidence that genes contribute to a person's chance of developing the disease.
The DecodeME study, said to be the largest of its kind in the world, uncovered eight areas of genetic code in people with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) that are markedly different to the DNA of people without the condition.
Researchers hope the findings will boost 'validity and credibility' for patients, and help rebuff some of the stigma and lack of belief that exists around the condition.
There is currently no diagnostic test or cure for ME/CFS, which is believed to affect around 67 million people worldwide, and very little is known about what causes it.
A key feature of the condition is a disproportionate worsening of symptoms following even minor physical or mental activity, which is known as post-exertional malaise (PEM,) while other symptoms include pain, brain fog and extreme energy limitations that do not improve with rest.
For the new study, researchers analysed 15,579 DNA samples from the 27,000 people with ME/CFS participating in DecodeME, described as the world's largest data set of people with the disease.
The eight regions of DNA where scientists found genetic differences involve genes linked to the immune and nervous systems.
At least two of the genetic signals relate to how the body responds to infection, which researchers said aligns with long-standing patient reports that the onset of symptoms often followed an infectious illness.
Professor Chris Ponting, DecodeME investigator from the University of Edinburgh, said: 'This is a wake-up call. These extraordinary DNA results speak the language of ME/CFS, often recounting people's ME/CFS symptoms.
'DecodeME's eight genetic signals reveal much about why infection triggers ME/CFS and why pain is a common symptom.
'ME/CFS is a serious illness and we now know that someone's genetics can tip the balance on whether they are diagnosed with it.'
As a person's DNA does not change over time, experts say the genetic signals identified would not have developed because of ME/CFS and are therefore likely to reflect the causes of the disease.
Populations used in the initial study were limited to those from European ancestries.
DecodeME research studying DNA data from all ancestries is ongoing.
ME/CFS, thought to affect around 404,000 people in the UK, affects more females than males, although researchers found nothing to explain why this is the case.
The DecodeME team is now calling on researchers from around the world to access its 'rich' dataset and help drive forward targeted studies into ME/CFS.
Sonya Chowdhury, chief executive of Action for ME and a DecodeME co-investigator, said: 'These results are groundbreaking.
'With DecodeME, we have gone from knowing next to nothing about the causes of ME/CFS, to giving researchers clear targets.'
She also hopes the discoveries will help change the way the condition is viewed.
Ms Chowdhury said: 'This really adds validity and credibility for people with ME.
'We know that many people have experienced comments like ME is not real, or they've been to doctors and been disbelieved or told that it's not a real illness.
'Whilst things have changed and continue to change, that is still the case for some people and we hear that repeatedly as a charity.
'Being able to take this study into the treatment room and say there are genetic causes that play a part in ME is going to be really significant for individuals.
'It will rebuff that lack of belief and the stigma that exists.'
The findings have been reported in a pre-print publication, or unpublished study.
During a media briefing about the study, researchers were asked about similarities between the symptoms of long Covid and ME/CFS.
Prof Ponting said: 'It's very clear that the symptomology between long Covid and ME is highly similar.
'Not for everyone but there are substantial similarities but as a geneticist the key question for me is are there overlapping genetic factors, and we haven't found that in DECode ME with the methods that we've employed.
' One of the key things that we're doing is enabling others to use their different approaches to ask and answer the same question.'
DecodeME is a collaboration between the University of Edinburgh, the charity Action for ME, the Forward ME alliance of charities, and people with ME/CFS.
It is funded by the Medical Research Council and National Institute for Health and Care Research.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
3 hours ago
- Times
NHS drug pricing gives cold comfort to Big Pharma
When the government launched its Life Sciences Sector Plan on July 16 the tone was buoyant and the aim impressive: to turn 'cutting-edge research into real-world results: new treatments, faster diagnosis, and more lives saved'. The 'roadmap' to these sunlit uplands was constructed around three 'core pillars': to enable world-class scientific research and development; to attract global capital and grow UK companies; and to deliver better outcomes for patients in a more modern, preventive healthcare system. Few would dare to argue with these noble aspirations. And the UK's life sciences industry, which is worth £108 billion and employs more than 300,000 people, has indeed long been seen as a jewel in the country's economic crown. But the shadow of potential decline has fallen across it in recent years, with a cautionary tale attached: its name is AstraZeneca. Britain's most valuable public company, presently worth £170 billion, has deep roots in this country: it was the result of a 1999 merger between Sweden's Astra and the UK's Zeneca Group, itself an offshoot of the British chemical behemoth ICI. Its chief executive, Sir Pascal Soriot, in situ since 2012, has shown a strong commitment to nurturing scientific discovery. That yielded its most dramatic benefits during the Covid-19 pandemic when AstraZeneca's vaccine, developed with Oxford University, was a British success story. Yet since then its relations with the UK government have not all been smooth sailing. In 2021, as a response to Britain's 'discouraging' taxes, the company located a £320 million new factory in Ireland rather than England. Sir Pascal was also unhappy with the decision by Nice, England's drug-approval body, to reject the firm's breast cancer drug Enhertu on cost grounds, despite its adoption in Scotland. Perhaps the most dispiriting episode, however, involved AstraZeneca's decision to abandon a proposed £450 million expansion of its vaccine plant in Speke, near Liverpool, after the incoming Labour government threatened to slash the subsidies it was previously offered. There have been worrisome murmurs of relisting in the US. • AstraZeneca boss demands big rise in NHS drug spending Those examples — and the dissatisfaction they indicate — have echoes in the wider mood in the life sciences industry. Many pharmaceutical companies feel that the UK has moved from striking a necessarily hard bargain on NHS drug prices to a resistant mindset that overly restricts patients' access to new treatments. Last year Paul Hudson, the British chief executive of the French company Sanofi, lamented a UK system that is slow to pass on medical advances: for every 100 patients that get a new medicine within its first year of production in EU countries, he said, only 21 UK patients enjoy the same benefit. The share of the UK health budget spent on new medicines has fallen to less than 10 per cent, compared with 15 per cent in France and 17 per cent in Germany. Meanwhile, companies say, overly tight NHS price-capping on drugs is now threatening investment in Britain. Clearly a balance must be struck between NHS budgetary restraints and encouraging life-changing research and development. Yet the warnings from AstraZeneca suggest that the pharmaceutical industry is being viewed through too myopic and punitive a lens, because it is easier to seek discounts on drugs than it is to improve NHS efficiency.
Times
4 hours ago
- Times
‘I thought I was going to die' — the GP who beat extreme stress
The doctors stood at the end of my bed, looking mystified. I was terrified — I thought I was going to die. I'd arrived at hospital three days before with an internal temperature of 42C; now my organs were failing. As a GP myself, I knew how serious my condition was. I was 39 with a wonderful husband, three beautiful children and a successful career but I didn't have an immune system strong enough to fight this fever. After four weeks in hospital I was eventually discharged with the unsatisfactory diagnosis of PUO — pyrexia of unknown origin — which basically means 'you were very hot but we don't know why'. • Read more expert advice on healthy living, fitness and wellbeing This was a life-changing moment. Whatever the diagnosis, the cause was clear to me: burnout. For years, I'd pushed my body to breaking point. Determined to see my children, then aged ten, nine and five, grow up, I decided that I needed to use my medical knowledge to reinvent myself. The biohacks (as the data analysis and habits I deployed to optimise my health are called) have proved so successful that now, aged 53, my biological age — that is, the age of my cells, ascertained with a blood test that analyses protein markers of inflammation, central to ageing — is that of a 20-year-old. Strange as it sounds, science shows we can bring our age down in a measurable way. I'm proof of this. And while biohacking might bring to mind wealthy tech titans trying to live for ever, many of the techniques I now teach clients as a longevity doctor are free, take minutes and can add decades to our lives. • How I got Rod Stewart, 80, fit to perform I believe we should set a goal for how long we want to live, just as we set goals for everything else, and work towards it. I tell clients that, with the right approach, there's no reason they can't make one million healthy hours, or 114 years. Unlikely as it might sound, that's my intention. Certainly, I feel barely recognisable from the partner in a GP practice who was too busy to go to the loo between patients, surviving on biscuits and writing prescriptions into the night after the children had gone to bed. I thought I could manage the juggle, never slowing down enough to notice the warning signs — constantly aching neck, waking up exhausted after four hours' sleep — that I was about to crash. I worked through the fever I developed one Friday morning in 2011 so as to not let colleagues down. But by the following afternoon I was too ill to eat, move or make decisions. My husband, Manish, a dentist who was then 42, rushed me to hospital near our London home where, thinking that my temperature must be caused by a severe infection, doctors put me on a potent intravenous antibiotic drip. • On the paradise island where millionaires go to avoid death (and taxes) When that didn't help they performed emergency abdominal surgery in the middle of the night as they suspected that an abscess in my abdomen could be to blame. It wasn't. Days later, weak from surgery and with my kidney and liver function deteriorating because of my continued high fever, there was still no discernible cause. It was a month before my temperature stabilised and I was able to be discharged. Recuperating at home I realised that my body's low resilience to stress after years of pushing myself to my limit had been to blame. In addition to regaining strength, I prioritised rest, nutrition and movement, which I had long advised patients were essential but had ignored myself. I started with sleep. I set an alarm for 9.30pm to remind me to switch off screens before going to bed at 10.30pm and getting up at 6.30am. Back at work after four months off, I finally learnt to delegate. I filled up on protein and fibre, bought a standing desk, scheduled an appointment with myself at 12.30pm every day to go for a lunchtime walk or run and started lifting weights daily (I kept them under my desk at work). As years passed and I felt stronger I realised there was more I could do to monitor my health than I'd learnt at medical school. I could identify the key factors that influence our biological age and test for them. • Be a super-ager — and join the 'wellderly' These included hormones. I discovered that my levels of the stress hormone cortisol — which contributes to inflammation when raised — still weren't dropping low enough at night to allow for deep sleep. I used light to regulate it, stepping outdoors on waking for a minute, and wearing glasses after 8pm that block the blue light emitted from screens that inhibits the release of the sleep-producing hormone melatonin. A glucose test revealed that my blood sugar levels weren't at optimum stability so I bought a continuous glucose monitor (CGM) — a device you attach to the back of your arm, available from chemists for around £50 — to track exactly what sent my blood sugar levels soaring via an app. Quinoa was an unlikely culprit for me, which certainly won't be the case for everyone, but shows why monitoring individual data is important. A DNA test revealed that my genes for endurance sport are stronger than my genes for strength. As I ran the London Marathon two years ago, I told myself I was 'made for this' — not as a generic pep talk but because I was genetically programmed to keep going. It helped. I numbered my most-used longevity biohacks from 1 to 10, with a correlating activity or time, to make them easier to remember. I don't do all ten hacks every day but focus on a handful at a time, telling my clients that no matter how busy they are, everyone can find 60 seconds. For example, 1-10 means spending one minute in morning sunlight followed by ten seconds setting an intention for the day; research has found people who have purpose live for seven years longer. Meanwhile, 3-30 involves taking three sips of water every 30 minutes — one study found those with a lower fluid intake have a 21 per cent higher risk of dying prematurely — and 5-50 means holding five stretches for 50 seconds a day, including one related to balance; a study of 1,700 people aged 51-75 found people who couldn't stand on one leg for at least 10 seconds had an 84 per cent higher risk of death after seven years. • I'm healthier in my 60s than I was 30 years ago: here's how The 6-60 entails slowing your breath to less than six breaths a minute for one minute, every hour, as slow breathing has been found to lower our stress response. Some of my strategies might sound extreme. I celebrated my 50th birthday alone and in silence in a cottage in the Spanish mountains for seven days, because silence is shown to lower stress and improve cognitive function. But everyone can achieve seven seconds of silence every 70 minutes (7-70). Paying compliments, meanwhile, is important because it releases the bonding hormone oxytocin, which can help reduce feelings of loneliness. Oxytocin has been shown to light up the same centre of the brain as physical pain and may play a role in reducing inflammation. I incorporate micro movements into my day — calf raises while I'm brushing my teeth, for example — and twice a week I have a sauna, because heat helps skin detox and stimulates the metabolism. I only eat between 10am and 6pm, as fasting encourages autophagy, or cell repair, and twice a year I do a water-only five-day fast, which sounds harder than it is. After three days your body's hunger signals quieten down because it's in clean-up mode. My husband and children — now aged 24, 23 and 20 — are supportive and biohack themselves to a certain extent. They wear smart rings or bands like me to track their sleep data, heart rate and VO2 max, use sleep masks and mouth tape in the night, love exercise and sport, and have tested their gut microbiome and metabolism. They're not fanatical about it but neither am I. Although I no longer drink alcohol, I still enjoy the occasional chocolate. When I started to study longevity I felt I was getting my wrists slapped by colleagues in the medical profession. One GP said that telling people they could hack their health was dangerous. Disturbed by the semantics rather than the science, they thought I was suggesting people take extreme or unsafe measures. But what could be more important than taking control of your health? Another said the role of GPs wasn't to stop people getting sick, at which point, in 2019, I left conventional general practice to set up my longevity business. That was when I started testing my biological age, which has remained at 20 ever since. Helping to prevent people get as ill as I did and reverse ageing by 10, 20 or even 30 years feels amazing. I look younger now — my children joke that I blossomed late — but more importantly I have so much more focus, energy and joy, which I plan to maintain for told to Antonia Hoyle
The Independent
5 hours ago
- The Independent
New evidence of giant gas planet around ‘Earth's closest solar twin'
Astronomers have found strong evidence of a giant gas planet orbiting a star in a solar system close to our own sun. Four light-years away from Earth, the Alpha Centauri triple-star system has long been a compelling target for scientists to search for worlds outside our solar system. Now, scientists have found a lifeless planet which could be a close neighbour to Earth in astronomical terms, and could even have moons that sustain life. The potential planet, detected last year, disappeared in follow-up observations. But astronomers found new signs using NASA 's powerful James Webb Space Telescope. If confirmed, the planet would be the closest to Earth that orbits in the habitable zone of a sun-like star. "Four years is a long way but in galaxy terms, it's very close - it's in our neighbourhood," Dr Carly Howett, associate professor of space instrumentation at the University of Oxford, told the BBC. "It is around a star that is sun-like and about the same temperature and brightness. That's really important if we want to think about habitable worlds.' However, because the planet candidate is a gas giant, scientists say it would not support life as we know it. Charles Beichman, from NASA's Jet Propulsion Laboratory and the NASA Exoplanet Science Institute at Caltech's IPAC astronomy center, said: 'With this system being so close to us, any exoplanets found would offer our best opportunity to collect data on planetary systems other than our own. 'Yet, these are incredibly challenging observations to make, even with the world's most powerful space telescope, because these stars are so bright, close, and move across the sky quickly,' he added. The stars create huge amounts of bright light which can block out nearby objects, which might explain why the potential planet appeared to disappear. Mr Beichman added: 'Webb was designed and optimised to find the most distant galaxies in the universe. The operations team at the Space Telescope Science Institute had to come up with a custom observing sequence just for this target, and their extra effort paid off spectacularly.' Confirmation of the potential planet would mark a new milestone for exoplanet imaging efforts, as it would be the closest to its star to be seen so far. 'It's also the most similar in temperature and age to the giant planets in our solar system, and nearest to our home, Earth," said PhD student Aniket Sanghi of Caltech, a co-first author on the two papers covering the team's research. "Its very existence in a system of two closely separated stars would challenge our understanding of how planets form, survive, and evolve in chaotic environments." Astronomers hope to use a new telescope, NASA's Nancy Grace Roman Space Telescope, which is set to launch by May 2027, equipped with dedicated hardware to test new technologies in the search for new life.
